Inhibitory effects of resveratrol on foam cell formation are mediated through monocyte chemotactic protein-1 and lipid metabolism-related proteins

International Journal of Molecular Medicine

Volumn 33, Issue 5, 2014, Pages 1161-1168

  Dong, Wenpeng ^a   Wang, Xianyue ^a   Bi, Shenghui ^a   Pan, Zhiguo ^a   Liu, Shenxi ^a   Yu, Hao ^a   Lu, Hua ^a   Lin, X I ^a   Wang, Xiaowu ^a   Ma, Tao ^a   Zhang, Weida ^a  

^a GUANGZHOU GENERAL HOSPITAL OF GUANGZHOU MILITARY COMMAND   (China)

Author keywords

Atherosclerosis; Inflammation; Lipid metabolism; Resveratrol; THP 1 cells

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LIPOPOLYSACCHARIDE; LOW DENSITY LIPOPROTEIN; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; OXIDIZED LOW DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHORBOL 13 ACETATE 12 MYRISTATE; RESVERATROL; SIRTUIN 1; SIRT1 PROTEIN, HUMAN; STILBENE DERIVATIVE;

ARTICLE; ATHEROSCLEROSIS; CELL DIFFERENTIATION; CONTROLLED STUDY; CULTURE MEDIUM; FOAM CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; INFLAMMATORY INFILTRATE; LIPID ANALYSIS; LIPID METABOLISM; LIPID STORAGE; MACROPHAGE; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; CELL LINE; CYTOLOGY; DRUG EFFECTS; METABOLISM;

CELL DIFFERENTIATION; CELL LINE; CHEMOKINE CCL2; FOAM CELLS; HUMANS; LIPID METABOLISM; LIPOPOLYSACCHARIDES; LIPOPROTEINS, LDL; MACROPHAGES; PPAR ALPHA; PPAR GAMMA; SIRTUIN 1; STILBENES; TETRADECANOYLPHORBOL ACETATE;

EID: 84899568203     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2014.1680     Document Type: Article

References (45)

1. Andersson J, Libby P and Hansson GK: Adaptive immunity and atherosclerosis. Clin Immunol 134: 33-46, 2010.
2. Hansson GK: Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352: 1685-1695, 2005.
3. Weber C, Zernecke A and Libby P: The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol 8: 802-815, 2008.
4. -/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394: 894-897, 1998.
5. Gu L, Okada Y, Clinton SK, et al: Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 2: 275-281, 1998. (Pubitemid 128373654)
6. Edfeldt K, Swedenborg J, Hansson GK and Yan ZQ: Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 105: 1158-1161, 2002. (Pubitemid 34225814)
7. Fan EG, Zhang LJ, Jiang S and Bai YH: Beneficial effects of resveratrol on atherosclerosis. J Med Food 11: 610-614, 2008.
8. Palmieri D, Pane B, Barisione C, et al: Resveratrol counteracts systemic and local inflammation involved in early abdominal aortic aneurysm development. J Surg Res 171: e237-246, 2011.
9. Prasad K: Natural products in regression and slowing of progression of atherosclerosis. Curr Pharm Biotechnol 11: 794-800, 2010.
10. Zhu X, Liu Q, Wang M, et al: Activation of Sirt1 by resveratrol inhibits TNF-alpha induced inflammation in fibroblasts. PLoS ONE 6: e27081, 2011.
11. Militaru C, Donoiu I, Craciun A, Scorei ID, Bulearca AM and Scorei RI: Oral resveratrol and calcium fructoborate supplementation in subjects with stable angina pectoris: effects on lipid profiles, inflammation markers, and quality of life. Nutrition 29: 178-183, 2013.
12. Voloshyna I, Hai O, Littlefield MJ, Carsons S and Reiss AB: Resveratrol mediates anti-atherogenic effects on cholesterol flux in human macrophages and endothelium via PPAR gamma and adenosine. Eur J Pharmacol 698: 299-309, 2013.
13. Vingtdeux V, Chandakkar P, Zhao H, Davies P and Marambaud P: Small-molecule activators of AMP-activated protein kinase (AMPK), RSVA314 and RSVA405, inhibit adipogenesis. Mol Med 17: 1022-1030, 2011.
14. Fullerton MD, Steinberg GR and Schertzer JD: Immunometabolism of AMPK in insulin resistance and atherosclerosis. Mol Cell Endocrinol 366: 224-234, 2013.
15. Siriwardhana N, Kalupahana NS, Cekanova M, LeMieux M, Greer B and Moustaid-Moussa N: Modulation of adipose tissue inflammation by bioactive food compounds. J Nutr Biochem 24: 613-623, 2013.
16. Crandall JP and Barzilai N: Exploring the promise of resveratrol: where do we go from here? Diabetes 62: 1022-1023, 2013.
17. Coll B, Alonso-Villaverde C and Joven J: Monocyte chemoattractant protein-1 and atherosclerosis: is there room for an additional biomarker? Clin Chim Acta 383: 21-29, 2007. (Pubitemid 47018251)
18. Charo IF and Taubman MB: Chemokines in the pathogenesis of vascular disease. Circ Res 95: 858-866, 2004. (Pubitemid 39435000)
19. McLaren JE, Michael DR, Ashlin TG and Ramji DP: Cytokines, macrophage lipid metabolism and foam cells: implications for cardiovascular disease therapy. Prog Lipid Res 50: 331-347, 2011.
20. Kallio KA, Buhlin K, Jauhiainen M, et al: Lipopolysaccharide associates with pro-atherogenic lipoproteins in periodontitis patients. Innate Immun 14: 247-253, 2008.
21. Vink A, Schoneveld AH, van der Meer JJ, et al: In vivo evidence for a role of toll-like receptor 4 in the development of intimal lesions. Circulation 106: 1985-1990, 2002. (Pubitemid 35176306)
22. Park D-W, Kim J-S, Chin B-R and Baek S-H: Resveratrol inhibits inflammation induced by heat-killed Listeria monocytogenes. J Med Food 15: 788-794, 2012.
23. Feng X, Zhang Y, Xu R, et al: Lipopolysaccharide up-regulates the expression of Fcalpha/mu receptor and promotes the binding of oxidized low-density lipoprotein and its IgM antibody complex to activated human macrophages. Atherosclerosis 208: 396-405, 2010.
24. Winnik S, Stein S and Matter CM: SIRT1 - an anti-inflammatory pathway at the crossroads between metabolic disease and atherosclerosis. Curr Vasc Pharmacol 10: 693-696, 2012.
25. Semple RK, Chatterjee VK and O'Rahilly S: PPAR gamma and human metabolic disease. J Clin Invest 116: 581-589, 2006. (Pubitemid 43326862)
26. Costa Cdos S, Rohden F, Hammes TO, et al: Resveratrol upregulated SIRT1, FOXO1, and adiponectin and downregulated PPARgamma1-3 mRNA expression in human visceral adipocytes. Obes Surg 21: 356-361, 2011.
27. Nimmagadda VK, Bever CT, Vattikunta NR, et al: Overexpression of SIRT1 protein in neurons protects against experimental autoimmune encephalomyelitis through activation of multiple SIRT1 targets. J Immunol 190: 4595-4607, 2013.
28. Cantó C, Jiang LQ, Deshmukh AS, et al: Interdependence of AMPK and SIRT1 for metabolic adaptation to fasting and exercise in skeletal muscle. Cell Metab 11: 213-219, 2010.
29. Hardie DG: AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol 8: 774-785, 2007.
30. + metabolism and SIRT1 activity. Nature 458: 1056-1060, 2009.
31. Costford SR, Bajpeyi S, Pasarica M, et al: Skeletal muscle NAMPT is induced by exercise in humans. Am J Physiol Endocrinol Metab 298: E117-E126, 2010.
32. Libby P: Inflammation in atherosclerosis. Nature 420: 868-874, 2002.
33. Hansson GK and Libby P: The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 6: 508-519, 2006. (Pubitemid 43980523)
34. Park D-W, Baek K, Kim J-R, et al: Resveratrol inhibits foam cell formation via NADPH oxidase 1-mediated reactive oxygen species and monocyte chemotactic protein-1. Exp Mol Med 41: 171-179, 2009.
35. Li H, Song Y, Li F, et al: Identification of lipid droplet-associated proteins in the formation of macrophage-derived foam cells using microarrays. Int J Mol Med 26: 231-239, 2010.
36. Hou X, Xu S, Maitland-Toolan KA, et al: SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase. J Biol Chem 283: 20015-20026, 2008.
37. Lagouge M, Argmann C, Gerhart-Hines Z, et al: Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127: 1109-1122, 2006. (Pubitemid 44894520)
38. Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM and Puigserver P: Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 434: 113-118, 2005. (Pubitemid 40349395)
39. Reverchon M, Cornuau M, Cloix L, et al: Visfatin is expressed in human granulosa cells: regulation by metformin through AMPK/SIRT1 pathways and its role in steroidogenesis. Mol Hum Reprod 19: 313-326, 2013.
40. Morita Y, Wada-Hiraike O, Yano T, et al: Resveratrol promotes expression of SIRT1 and StAR in rat ovarian granulosa cells: an implicative role of SIRT1 in the ovary. Reprod Biol Endocrinol 10: 14, 2012.
41. Picard F, Kurtev M, Chung N, et al: Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 429: 771-776, 2004. (Pubitemid 38833129)
42. Baur JA, Pearson KJ, Price NL, et al: Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444: 337-342, 2006. (Pubitemid 44764104)
43. von Grote EC, Venkatakrishnan V, Duo J and Stenken JA: Long-term subcutaneous microdialysis sampling and qRT-PCR of MCP-1, IL-6 and IL-10 in freely-moving rats. Mol Biosyst 7: 150-161, 2011.
44. Wang J, Si Y, Wu C, et al: Lipopolysaccharide promotes lipid accumulation in human adventitial fibroblasts via TLR4-NF-kappaB pathway. Lipids Health Dis 11: 139, 2012.
45. Culpitt SV, Rogers DF, Fenwick PS, et al: Inhibition by red wine extract, resveratrol, of cytokine release by alveolar macrophages in COPD. Thorax 58: 942-946, 2003. (Pubitemid 37392803)